LONDON and PHILADELPHIA – March 17, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced it will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA.
Details of the two presentations:
Title: AVA6103 is a FAP-enabled pre|CISION® peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity
Authors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Michelle Morrow, Francis Wilson
Poster number and Location: 5846, Section 17, Board 15
Session: Tumor Microenvironment, Multi-specifics, and Immunomodulation
Section: Experimental and Molecular Therapeutics
Timing: Tuesday, 21 April 2026, 2:00-5:00pm PDT
Title: Characterization and translational development of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage
Authors: Victoria Juskaite, Tom Clough, Ellen Watts , Alexa Kennedy, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Greg Billenness, Douglas Sammon, Sophie Brown, Curtis Rink , Ruairidh Edwards, Vidicha Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David Jones
Poster number and Location: 5656, Section 10, Board 26
Session: Antibody-Drug Conjugates and Linker Engineering 4
Section: Experimental and Molecular Therapeutics
Timing: Tuesday 21 April 2026, 2:00-5:00pm PDT